Evidence map›Paper›PMID 31380450›Full record

ArticleAsia Oceania journal of nuclear medicine & biology2019

Utility of

Hiroshi Wakabayashi, Tahahiro Konishi, Hiroto Yoneyama, Anri Inaki, Tomo Hiromasa, Takafumi Yamase, Norihito Akatani, Satoru Watanabe, Hiroshi Mori, Daiki Kayano and 1 more

Open access · greenAbstract read
In one paragraph

Article in Asia Oceania journal of nuclear medicine & biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Hiroshi WakabayashiDepartment of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Japan.
Tahahiro KonishiDepartment of Radiological Technology, Kanazawa University Hospital, Kanazawa, Japan.
Hiroto YoneyamaDepartment of Radiological Technology, Kanazawa University Hospital, Kanazawa, Japan.
Anri InakiDepartment of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Japan.
Tomo HiromasaDepartment of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Japan.
Takafumi YamaseDepartment of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Japan.
Norihito AkataniDepartment of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Japan.
Satoru WatanabeDepartment of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Japan.
Hiroshi MoriDepartment of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Japan.
Daiki KayanoDepartment of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Japan.
Seigo KinuyaDepartment of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Japan.
Kanazawa University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesSingle-photon emission computed tomography (SPECT) using metaiodobenzylguanidine (MIBG) is an important diagnostic tool for the treatment of refractory pheochromocytoma and paraganglioma (PPGL). Owing to the difficulty of SPECT quantification, the tumour-to-background ratio (TBR) is used to assess disease activity. However, the utility of TBR is limited owing to the background setting. A quantification technique of SPECT/computed tomography (CT) would facilitate image interpretation. This study aimed to assess the relationship between

methodsThis study included 15 patients with refractory PPGL who underwent

resultsAll patients had MIBG-avid lesions, as seen on

conclusion

Indexed as

123I-MIBGParagangliomaRefractory pheochromocytoma

Identifiers

PMID31380450
PMCPMC6661310
OpenAlexW2921029987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.